TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS WITH NITROGEN CONTAINING BISPHOSPHONATES, EARLY SIDE EFFECTS AND THEIR PREVENTION

Infusions of aminobisphosphonates are now established therapies ofpostmenopausal osteoporosis. Their use is associated with fever and musculoskeletal pain in some subjects, referred to as the acute phase response (APR). The purpose of the study was to explore tolerability of zoledronic acid in the t...

Full description

Bibliographic Details
Main Authors: O V Yakushevskaya, S V Yureneva
Format: Article
Language:English
Published: Endocrinology Research Centre 2013-12-01
Series:Остеопороз и остеопатии
Subjects:
Online Access:https://endojournals.ru/index.php/osteo/article/view/8863
id doaj-345d957966aa48959bcd9192c61e5068
record_format Article
spelling doaj-345d957966aa48959bcd9192c61e50682021-07-02T21:14:55ZengEndocrinology Research CentreОстеопороз и остеопатии2072-26802311-07162013-12-01163171910.14341/osteo2013317-197908TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS WITH NITROGEN CONTAINING BISPHOSPHONATES, EARLY SIDE EFFECTS AND THEIR PREVENTIONO V Yakushevskaya0S V Yureneva1ФГБУ Научный центр акушерства, гинекологии и перинатологии им. акад.В.И. Кулакова Минздрава РоссииФГБУ Научный центр акушерства, гинекологии и перинатологии им. акад.В.И. Кулакова Минздрава РоссииInfusions of aminobisphosphonates are now established therapies ofpostmenopausal osteoporosis. Their use is associated with fever and musculoskeletal pain in some subjects, referred to as the acute phase response (APR). The purpose of the study was to explore tolerability of zoledronic acid in the treatment of postmenopausal osteoporosis. In a 36-month open label, prospective study patients with postmenopausal osteoporosis iv received zoledronic acid at a dose of 5 mg every 12 months. We then analyzed the tolerability of the treatment at the hospital and via telephone interviews during the next 14 days and every 3 months after the infusion. Prevention of APR was carried out with paracetamol 500 mg x 3 times a day on the day of first infusion and the next 2 days. Symptoms of APR were recorded in 39% (n=43) of patients with prevention therapy. APR developed in the first 12-24 hours after infusion of zoledronic acid. Among women without prevention APR developed in 65% (n=75) of cases. (OR=0.34 CI (0.2-0.59)). After the 2 nd infusion symptoms of APR were noted in 27.9% (n=26) (р<0.05) of 93 patients, after the 3 rdin 6.6% (n=2) of 30 patients. Thus, in >90% of cases the symptoms were of mild or moderate severity, with resolution within 3 days after infusion of zoledronic acid. The most frequent symptoms were bone and muscular manifestations and a flu-like syndrome (p<0.05). APR developed during the first 12-24 hours after infusion of zoledronic acid. ARR developed 2.5 times more often in the cases when zoledronic acid was used for the first time. If paracetamol treatment was administered, APR cases were documented 1.7 times less often with lesser degree and length of manifestations. Frequency of APR dropped after repeated zoledronic acid infusions.https://endojournals.ru/index.php/osteo/article/view/8863постменопаузальный остеопорозбисфосфонатыреакция острой фазызоледроновая кислота
collection DOAJ
language English
format Article
sources DOAJ
author O V Yakushevskaya
S V Yureneva
spellingShingle O V Yakushevskaya
S V Yureneva
TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS WITH NITROGEN CONTAINING BISPHOSPHONATES, EARLY SIDE EFFECTS AND THEIR PREVENTION
Остеопороз и остеопатии
постменопаузальный остеопороз
бисфосфонаты
реакция острой фазы
золедроновая кислота
author_facet O V Yakushevskaya
S V Yureneva
author_sort O V Yakushevskaya
title TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS WITH NITROGEN CONTAINING BISPHOSPHONATES, EARLY SIDE EFFECTS AND THEIR PREVENTION
title_short TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS WITH NITROGEN CONTAINING BISPHOSPHONATES, EARLY SIDE EFFECTS AND THEIR PREVENTION
title_full TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS WITH NITROGEN CONTAINING BISPHOSPHONATES, EARLY SIDE EFFECTS AND THEIR PREVENTION
title_fullStr TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS WITH NITROGEN CONTAINING BISPHOSPHONATES, EARLY SIDE EFFECTS AND THEIR PREVENTION
title_full_unstemmed TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS WITH NITROGEN CONTAINING BISPHOSPHONATES, EARLY SIDE EFFECTS AND THEIR PREVENTION
title_sort treatment of postmenopausal osteoporosis with nitrogen containing bisphosphonates, early side effects and their prevention
publisher Endocrinology Research Centre
series Остеопороз и остеопатии
issn 2072-2680
2311-0716
publishDate 2013-12-01
description Infusions of aminobisphosphonates are now established therapies ofpostmenopausal osteoporosis. Their use is associated with fever and musculoskeletal pain in some subjects, referred to as the acute phase response (APR). The purpose of the study was to explore tolerability of zoledronic acid in the treatment of postmenopausal osteoporosis. In a 36-month open label, prospective study patients with postmenopausal osteoporosis iv received zoledronic acid at a dose of 5 mg every 12 months. We then analyzed the tolerability of the treatment at the hospital and via telephone interviews during the next 14 days and every 3 months after the infusion. Prevention of APR was carried out with paracetamol 500 mg x 3 times a day on the day of first infusion and the next 2 days. Symptoms of APR were recorded in 39% (n=43) of patients with prevention therapy. APR developed in the first 12-24 hours after infusion of zoledronic acid. Among women without prevention APR developed in 65% (n=75) of cases. (OR=0.34 CI (0.2-0.59)). After the 2 nd infusion symptoms of APR were noted in 27.9% (n=26) (р<0.05) of 93 patients, after the 3 rdin 6.6% (n=2) of 30 patients. Thus, in >90% of cases the symptoms were of mild or moderate severity, with resolution within 3 days after infusion of zoledronic acid. The most frequent symptoms were bone and muscular manifestations and a flu-like syndrome (p<0.05). APR developed during the first 12-24 hours after infusion of zoledronic acid. ARR developed 2.5 times more often in the cases when zoledronic acid was used for the first time. If paracetamol treatment was administered, APR cases were documented 1.7 times less often with lesser degree and length of manifestations. Frequency of APR dropped after repeated zoledronic acid infusions.
topic постменопаузальный остеопороз
бисфосфонаты
реакция острой фазы
золедроновая кислота
url https://endojournals.ru/index.php/osteo/article/view/8863
work_keys_str_mv AT ovyakushevskaya treatmentofpostmenopausalosteoporosiswithnitrogencontainingbisphosphonatesearlysideeffectsandtheirprevention
AT svyureneva treatmentofpostmenopausalosteoporosiswithnitrogencontainingbisphosphonatesearlysideeffectsandtheirprevention
_version_ 1721322256350576640